Today's Daily Dose brings you news about Aurinia Pharma's secondary offering; Aptose Biosciences' early clinical data of CG-806 and APTO-253; the proposed reverse stock split of Protalix BioTherapeutics and Gilead's path forward for KTE-X19 in the treatment for relapsed or refractory mantle cell lymphoma.
from RTT - Biotech https://ift.tt/33ZRkPe
via IFTTT
No comments:
Post a Comment